Alysha Schlack, NP
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,250 of the $22,825 with a category attached, or 71.2%. AstraZeneca accounts for 89.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $12,257 and has fallen 65.7% since, to $4,207 in 2025. Among family clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $207.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- Boehringer Ingelheim$492
- GSK$477
- Actelion Pharmaceuticals US, Inc.$339
- Insmed, Inc.$209
- Advanced Respiratory, Inc$148
- plus $755 from 9 others
What the payments were for
- Speaking & faculty fees$16,25071%
- Travel & lodging$2,1459%
- Food & beverage$4,43119%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $20,406 |
| Boehringer Ingelheim | 15 | $492 |
| GSK | 9 | $477 |
| Actelion Pharmaceuticals US, Inc. | 3 | $339 |
| Insmed, Inc. | 3 | $209 |
| Advanced Respiratory, Inc | 2 | $148 |
| Pulmonx Corporation | 1 | $146 |
| Grifols USA, LLC | 2 | $123 |
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Sanofi | 1 | $100 |
| Baxter Healthcare | 4 | $99 |
| United Therapeutics Corporation | 1 | $96 |
| Genentech USA, Inc. | 1 | $27 |
| Fisher & Paykel Healthcare Inc | 1 | $21 |
| Electromed, Inc. | 3 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$18,901
- UPTRAVI$339
- OPSUMIT$339
- BREZTRI$336
- OFEV$247
- CHARTIS CATHETER$146
- ZEPHYR DELIVERY CATHETER$146
- ZEPHYR ENDOBRONCHIAL VALVE$146
- PULMONX CHARTIS TABLET CONSOLE$146
- IMFINZI$130
- Arikayce$125
- XYWAV$122
- NUCALA$122
- Prolastin-C Liquid$109
- TEZSPIRE$106
How this compares
$22,825 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 533 | $413,206 |
| OfevNintedanib Esylate | 14 | $173,279 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 140 | $103,862 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 165 | $98,546 |
| Spiriva RespimatTiotropium Bromide | 101 | $65,927 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 97 | $65,277 |
| Dupixent PenDupilumab | 11 | $48,612 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $46,898 |
| Ambrisentan | 14 | $34,599 |
| Advair HfaFluticasone Propion/Salmeterol | 67 | $34,279 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 41 | $25,232 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $23,494 |
| Spiriva HandihalerTiotropium Bromide | 24 | $16,922 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 128 | $15,753 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $12,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $477 | $549,855780 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $492 | $362,984321 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Daliresp, Airsupra | $20,406 | $143,863242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Idaho.
Other family in Nampa
- Bobbi BullockNampa$609K
- Kate ClarkNampa$5K
- Deo PeppersackNampa$5K
- Troy CarrNampa$4K
- Michael ParkerMeridian$69K
- Jessica BraksiekBoise$41K
- Travis BlaserBoise$33K
- Jennifer WatsonCoeur D Alene$21K
- Amber MasseIdaho Falls$17K
- Brian KittelsonMeridian$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.